Cargando…
Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add‐on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA‐PRIME)
AIM: To compare (in the LIRA‐PRIME [NCT02730377], a randomized open‐label trial), the efficacy of liraglutide in controlling glycaemia versus an oral antidiabetic drug (OAD) in patients with uncontrolled type 2 diabetes (T2D), despite metformin use in a primary care setting (n = 219 sites, n = 9 cou...
Autores principales: | Unger, Jeff, Allison, Dale C., Kaltoft, Margit, Lakkole, Kavitha, Panda, Jayant K., Ramesh, Chethana, Sargin, Mehmet, Smolyarchuk, Elena, Twine, Melissa, Wolthers, Benjamin, Yarimbas, Gizem, Zoghbi, Marouan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298244/ https://www.ncbi.nlm.nih.gov/pubmed/34622567 http://dx.doi.org/10.1111/dom.14566 |
Ejemplares similares
-
Trial design and baseline data for LIRA‐PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting
por: Unger, Jeff, et al.
Publicado: (2019) -
Efficacy of liraglutide added to sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post‐hoc analysis of LIRA‐ADD2SGLT2i
por: Blonde, Lawrence, et al.
Publicado: (2021) -
OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Blonde, Lawrence, et al.
Publicado: (2019) -
Liraglutide as add‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial
por: Blonde, Lawrence, et al.
Publicado: (2020) -
Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre‐trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin
por: Meneghini, L., et al.
Publicado: (2019)